Eptifibatide NDC 71288-413

NDC codes

FDA NDC Directory

Product NDC (as listed)71288-413Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71288-0413Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71288-413-51	71288041351	1 VIAL, SINGLE-DOSE in 1 CARTON (71288-413-51) / 100 mL in 1 VIAL, SINGLE-DOSEMarketed from May 9, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Eptifibatide
Generic name (nonproprietary): eptifibatide
Active ingredients: Eptifibatide — .75 mg/mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: Meitheal Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213599
Marketing start: May 9, 2024
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Platelet Aggregation (Physiologic effect)
Identifiers: Product ID 71288-413_a15dafa6-7923-4999-8938-28e580304e57SPL ID a15dafa6-7923-4999-8938-28e580304e57SPL set ID 3e7e7cd3-8efa-4d91-a5ab-7fd78b0cc65eRxCUI 200349, 1736470UNII NA8320J834
Pharmacologic class: Platelet Aggregation Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N471288041351 followed by a unit qualifier and the quantity

Package 71288-0413-51. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 14, 2024.

Indications (excerpt from the label)

Eptifibatide Injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) 1.1 Acute Coronary Syndrome (ACS) Eptifibatide Injection is indicated to decrease the rate of a combined endpoint of death or new myocardial infarction (MI) in patients with ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). 1.2 Percutaneous Coronary Intervention (PCI) Eptifibatide Inject…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213599

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213599
Product	Strength	Form · route	Labeler	Product NDC
Eptifibatide	Eptifibatide 2 mg/mL	Injection, SolutionIntravenous	Meitheal Pharmaceuticals Inc.	71288-412